Hospital Discharge Medication Reconciliation Errors
Summary
The facility failed to accurately reconcile hospital discharge orders for three residents and failed to notify the medical provider of orders that required follow-up after a hospitalization. For one resident with diabetes, anxiety, depression, hyperlipidemia, and aphasia following a stroke, the hospital discharge medication list from the February 2025 return to the facility included several medications to be held pending provider review, including dapagliflozin, lisinopril-hydrochlorothiazide, metformin, and semaglutide, and also included atorvastatin and duloxetine to resume. The resident’s record did not show that the provider was notified about the held medications, and the MAR showed that none of the listed medications were given after the return from the hospital. That resident remained in the facility for months afterward, and later laboratory results showed worsening glucose control, with glucose and A1c values rising over time. Facility notes documented that the ARNP reviewed the December 2025 labs and planned to address them later, but the record did not show another ARNP visit until February 2026, and that visit did not document the rising A1c trend or the elevated glucose. In May 2026, the resident showed weakness and other changes in condition, but nursing assessments documented vital signs without a blood sugar check. The resident was later sent to the hospital, where the ED documented altered mental status, increased thirst, lethargy, slurred speech, disorientation, and a blood glucose of 1200. The hospitalization included diagnoses of hyperosmolar hyperglycemic state, severe sepsis, acute cystitis with hematuria, acute kidney injury, metabolic encephalopathy, and metabolic acidosis. For another resident, the hospital discharge orders after a February 2026 hospitalization included increased hydralazine, discontinuation of metformin, and new insulin orders, but the facility did not implement the discharge changes as ordered. The resident continued to receive the prior hydralazine dose, metformin was resumed and then later discontinued, and the ordered short-acting insulin was not started at discharge. Facility blood pressure records later showed repeated systolic readings above 180, including several readings over 200. A progress note later documented that the ARNP increased blood pressure medication and insulin and began sliding scale insulin. For a third resident admitted from an acute care hospital in April 2026, the hospital medication list included amoxicillin, hydromorphone, docusate sodium, and oxycodone. The facility entered the orders incorrectly: amoxicillin was transcribed at half the ordered dose, hydromorphone was entered as 1 tablet every 8 hours as needed instead of 0.5 tablet three times daily as needed before dressing changes, and docusate and oxycodone also required correction. The resident received 10 doses of the incorrect hydromorphone dose in April. Staff interviews showed confusion about the hospital orders, the allergy warning, and whether the dosage had been discussed with the ARNP, and the double-check process did not identify the hydromorphone error.
Penalty
Resources
Below are regulatory guidelines relevant to this citation:
Trusted data from CMS and state health departments
Every citation, penalty and Plan of Correction is sourced from public CMS records (latest release July 29, 2026) and official state health department websites — never guesswork.
In your survey window? See what surveyors are citing.
The Survey-Prep Report maps your facility's risk from 12 months of CMS and state citation data — what's being cited around you and what to check first. $129 one-time.